CAI/II-IN-12
CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma[1].
Product Specifications
UNSPSC
12352005
Target
Carbonic Anhydrase
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer; Neurological Disease
Smiles
O=S(C1=CC=C(C)C=C1)(OC2=CC=CC(/C=N/N3C(CC4=CC=C(C)C=C4)=NN(C(C)=O)C3=O)=C2)=O
Molecular Formula
C26H24N4O5S
Molecular Weight
504.56
References & Citations
[1]Medetalibeyoğlu H, et al. Synthesis and Computational Evaluation of N Acetyl-Derived Schiff Bases Incorporating 1,2,4-Triazoles for Dual Inhibition of Prostate Cancer Cells and Carbonic Anhydrases. ACS Omega. 2025 Aug 22;10 (34) :38585-38608.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CA II; CA I
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
